Navigation Links
InVitria Announces Launch of Recombinant Albumin for Diagnostics
Date:4/17/2009

Fort Collins, CO, April 17, 2009 / b3c newswire / - Addressing significant product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products. InVitria’s Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA). 
  • The advantages of Recombinant Albumin-DX include:
  • Reduce non-specific binding and improve specificity;
  • Improved consistency due to recombinant manufacturing;
  • Improved stabilization of sensitive proteins and biomarkers; and
  • Reduce occupational safety risk and regulatory burden of handling human or animal blood products.
Customer testing has shown that Recombinant Albumin-DX (Lipid-Free) increased biomarker activity to levels twice as high as the current commercial alternative. In addition, stability over time was significantly improved with Recombinant Albumin-DX (Lipid-Free). Tests have also shown the bioequivalence of the Recombinant Albumin-DX to native human serum albumin (HSA).  
 
“InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise,” said the company’s President and CEO Scott Deeter. “Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek.”
 
To receive a Recombinant Albumin-DX or DX Lipid-Free product materials packet, please contact InVitria’s customer service specialists at 1-800-916-8311 or by e-mail at info@InVitria.com.
ws" timex="4/17/2009 5:26:57 AM" dirsub="(bsp; About InVitria InVitria develops ...)" id="8019" index="biology" dir="InVitria Announces Launch of Recombinant Albumin for Diagnostics" dir2="InVitria Announces Launch of Recombinant Albumin for D..." keywords1=",biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters" keywords="InVitria,Announces,Launch,of,Recombinant,Albumin,for,Diagnostics" description="bsp; About InVitria InVitria develops manufactures and markets a portfolio of cell culture and diagnostic reagents. These products are used in cell culture biopharmaceutical formulation stem cell & regenerative medicine medical devices and diagnostics.   Learn more about InVitria’s products at a target _blank href http://www.in" url=u&"/biology-news-1/InVitria-Announces-Launch-of-Recombinant-Albumin-for-Diagnostics-8019-2/" title="InVitria%20Announces%20Launch%20of%20Recombinant%20Albumin%20for%20Diagnostics" %> InVitria Announces Launch of Recombinant Albumin for D... (Fort Collins CO April 17 2009 / b3c news...)
InVitria Announces Launch of Recombinant Albumin for Diagnostics
Date:4/17/2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... replacement at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica ... technology and host a hands-on workshop for surgeons to experience the simplicity of ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/21/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, today presented data from two clinical ... 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers ... In a Phase Ib/II study of napabucasin ... cancer stemness pathways by targeting STAT3 – colorectal cancer ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
Breaking Biology Technology: